Orchid Pharma Ltd (LSE:OCPA) - Share price - Overview

Stock Report

Orchid Pharma Ltd OCPA

Last Price
$-

Day Change
-|-%

As of -
- | USD
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap-
52-Wk Range-
Yield %-
ISINUS68572Y1001
Volume-
P/E-
P/S-
P/CF-

Share Price

Total Returns 18/07/2018

 Chg (%)  
More ...
Orchid Pharma Ltd0.00 
FTSE 100 TR GBP-0.75
 
Financials
201520162017
More ...
Income Statement
Turnover-8,734.397,965.04
Operating Profit-255.21-1,072.12
Net Profit--2,791.13-4,904.91
Reported EPS--32.07-55.13
Balance Sheet
Current Assets-12,511.988,791.36
Non Current Assets-26,108.7424,788.61
Total Assets-38,620.7233,579.97
Current Liabilities-13,376.1815,407.18
Total Liabilities-38,130.2737,456.63
Total Equity-490.45-3,876.66
Cash Flow
Operating Cash Flow-2,121.963,170.08
Net Change in Cash--756.25-578.76

Company Profile

Orchid Pharma Ltd is involved in the development, manufacturing and marketing of diverse bulk actives, formulations, and nutraceuticals. The company produces various products for cardiovascular, anti-diabetic, neuropsychiatry, and others.

Sector

Drug Manufacturers - Major

Index

Ratios
Comp
More ...
PER (E)27.15
Div Yld (E)0.00
PEG (E)0.00
ROCE-11.99
Op Mrgn-0.14
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Date06/07/1019/07/11
Ex-Div08/07/1015/07/11
Paidt.b.c.12/08/11
Amnt0.210.07
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.